ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 187 for:    BI10773

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02172196
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : June 24, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and sitagliptin were determined when both drugs were given in combination compared with BI 10773 or sitagliptin given alone.

Condition or disease Intervention/treatment Phase
Healthy Drug: BI 10773 Drug: Sitagliptin Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relative Bioavailability of Both BI 10773 and Sitagliptin After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Sitagliptin (100 mg q.d.) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)
Study Start Date : May 2009
Actual Primary Completion Date : July 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment sequence ABC
  1. Treatment A: BI 10773 once daily from day 1 to 5
  2. Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
  3. Treatment C: Sitagliptin once daily from day 1 to 5
Drug: BI 10773
Drug: Sitagliptin
Experimental: Treatment sequence CAB
  1. Treatment C: Sitagliptin once daily from day 1 to 5
  2. Treatment A: BI 10773 once daily from day 1 to 5
  3. Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
Drug: BI 10773
Drug: Sitagliptin



Primary Outcome Measures :
  1. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Days 1-8 ]
  2. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Days 1-8 ]

Secondary Outcome Measures :
  1. C24,N (concentration of analyte in plasma at 24 hours post-drug administration after administration of the Nth dose) [ Time Frame: Days 1-8 ]
  2. λz,ss (terminal half-life of the analyte in plasma) [ Time Frame: Days 1-8 ]
  3. t½,ss (terminal half-life of the analyte in plasma at steady state) [ Time Frame: Days 1-8 ]
  4. tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ) [ Time Frame: Days 1-8 ]
  5. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) [ Time Frame: Days 1-8 ]
  6. CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state) [ Time Frame: Days 1-8 ]
  7. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) [ Time Frame: Days 1-8 ]
  8. Aet1-t2,ss (amount of analyte eliminated in urine at steady state over a uniform dosing interval τ) [ Time Frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing ]
  9. fet1-t2,ss (fraction of analyte excreted unchanged in urine at steady state over a uniform dosing interval τ) [ Time Frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing ]
  10. CLR,ss (renal clearance of the analyte at steady state) [ Time Frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing ]
  11. UGE0-24 (Urinary glucose excretion of the analyte in urine over the time interval from time zero to 24 h) [ Time Frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing ]
  12. Abnormal findings in physical examination [ Time Frame: Baseline and within 3-10 days after last study drug administration ]
  13. Changes from baseline in vital sings (blood pressure, pulse rate) [ Time Frame: Baseline, day 1 and within 3-10 days after last study drug administration ]
  14. Changes from baseline in 12-lead ECG (electrocardiogram) [ Time Frame: Baseline and within 3-10 days after last study drug administration ]
  15. Changes from baseline in clinical laboratory tests [ Time Frame: Baseline, day 1, 5 and within 3-10 days after last study drug administration ]
  16. Incidence of adverse events [ Time Frame: up to 28 days ]
  17. Assessment of tolerability by investigator on a 4-point scale [ Time Frame: Within 3-10 days after last study drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers according to the following criteria:

    • Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
  • Age 18 to 50 years (incl.)
  • BMI 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion Criteria:

  • Any finding of the medical examination deviating from normal and of clinical relevance. Repeated measurement of a systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
  • Any evidence of a clinically relevant concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
  • Intake of drugs within one month or less than 10 half-lives of the respective drug prior to first study drug administration except if a relevant interaction can be ruled out
  • Participation in another trial with an investigational drug within two months prior to first study drug administration
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (average consumption of more than 30 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to the start of study)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for TdP (Torsades de pointes) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02172196     History of Changes
Other Study ID Numbers: 1245.27
First Posted: June 24, 2014    Key Record Dates
Last Update Posted: June 24, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Empagliflozin
Sitagliptin Phosphate
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action